In March, 2005, we established a dedicated state-of-the-art research and development facility, Strides Technology and Research, or STAR which has a 350 strong team working on areas relating to formulation development, quality assurance, analytics development, technology transfer, strategic sourcing, dossier preparation and regulatory filings. Our innovative formulation development skill sets, combined with competitive developments costs and the ability to provide end-to-end customer support, have established the Division as a value added growth engine.

  Our strong R&D capabilities have enabled us to build and maintain a strong product pipeline which together with our regulatory strengths, have resulted in quick registrations in regulated markets. We currently have over ___ product registrations in approximately ___ countries with ____ products under registration and a significant number of USFDA ANDA filings.  

On soft gel capsules alone, we have filed over 10 patent applications. Our innovative research and development have resulted in innovative drug delivery systems like Cyclosporine in SGC as micro emulsion pre-concentrate bioequivalent to Neoral, Ritonavir in solubilized form bioequivalent to Norvir, cold and cough formulations in clear gels and enteric coating of Omega 3,6 and 9 capsules. Continuing to raise the bar in developing new therapeutic formats, the R&D Division is currently actively engaged in the development of paediatric doses for antiretroviral and anti-tuberculosis drugs.

   As the R&D Division continues in its quest to create differentiated delivery formats and provide end-to-end customer support, its value and significance to Strides will only be enhanced.